Business
Pro Medicus (ASX:PME) share price in focus after broker upgrade
The Pro Medicus Limited (ASX: PME) share price has been a strong performer in 2021.
Since the start of the year, the health imaging company’s shares have rallied an impressive 27% higher.
This means the Pro Medicus share price has now doubled in value over the last 12 months.
Is it too late to buy Pro Medicus shares?
The good news for investors is that it may not be too late to buy Pro Medicus shares.
According to a note out of Goldman Sachs this morning, the broker has upgraded its shares to a buy rating with a $53.80 price target.
This price target implies potential upside of approximately 20% over the next 12 months.
Why is Goldman Sachs bullish on Pro Medicus?
Goldman has been impressed with the way the company continues to
-
General23 hours agoOsborne Park Football Club suspended for two years after Stephen Hawking costume controversy
-
General24 hours agoMelbourne Cup five quick hits: Melham magic, Blake Shinn falls, and concern over blood from Half Yours’s mouth
-
General20 hours agoQueensland medical professionals to take industrial action as negotiations with state government stall
-
Business24 hours ago5 super ASX ETFs to buy with $10,000